PremiumStock Analysis & Ideas2 Pharma-Focused ETFs with More Than 20% Upside – December 20233y agoIHEXPH
PremiumMarket News3 Best ETFs With 50%+ Upside to Buy in August 2026, According to Analysts13h agoHUTXYZ
PremiumCompany AnnouncementsTrevi Therapeutics Advances IPF Program with Completed NAL ER Safety Study18h agoTRVI
PremiumRatingsAlumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target1d agoALMS
Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target